Dannielle Appelhans - Aug 31, 2021 Form 4 Insider Report for Rubius Therapeutics, Inc. (RUBY)

Role
Chief Operating Officer
Signature
/s/ Joanne M. Protano, Attorney-in-Fact
Stock symbol
RUBY
Transactions as of
Aug 31, 2021
Transactions value $
$0
Form type
4
Date filed
9/1/2021, 08:12 PM
Previous filing
Aug 16, 2021
Next filing
Feb 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RUBY Stock Option (Right to Buy) Award $0 +150K $0.00 150K Aug 31, 2021 Common Stock 150K $21.72 Direct F1
transaction RUBY Restricted Stock Units Award $0 +50K $0.00 50K Aug 31, 2021 Common Stock 50K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest on August 9, 2022, then in 12 equal quarterly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3 The shares underlying the restricted stock units will vest in four equal annual installments beginning on August 9, 2022.